Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.67 |
| ▸ | MMP13 | P45452 | 8/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756448 | 0.90 | MAPT (0.69) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL7071567 | 0.81 | MAPT (1.00) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL18003076 | 0.80 | MAPT (0.76) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL4454103 | 0.80 | MAPT (0.80) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL15972463 | 0.80 | MAPT (0.79) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL2011209 | 0.78 | POLB (0.51) | MAPTRAB9ANPC1POLBL3MBTL1 | |
| SCHEMBL1756392 | 0.77 | POLB (0.52) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL17414642 | 0.76 | POLB (0.48) | MAPTRAB9ANPC1HSP90AA1MMP13 | |
| SCHEMBL17414635 | 0.76 | POLB (0.51) | MAPTRAB9ANPC1HSP90AA1POLB | |
| SCHEMBL17414636 | 0.76 | MAPT (0.48) | MAPTRAB9ANPC1HSP90AA1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | MAPT 2223/4885RAB9A 2816/4885NPC1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.